ArticleTranslational vision science & technology2026
Degradable Suture-Free Scaffold to Induce Therapeutic Ridge Formation and to Control Eye Elongation: A Potential Treatment for Pathological Myopia.
Article in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- [Research progress and applications of biologically derived materials in scleral reconstruction].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The purpose of this study was to develop an optimized treatment for pathological myopia: a degradable cell-free suture-free tissue scaffold implant that reverses the excessive axial elongation and induces a therapeutic ridge. Methods: A form-deprivation (FD) myopia model was established in New Zealand White rabbits. Comprised of gelatin methacryloyl and a poly-L-lactide microfiber film, the tissue scaffold was implanted onto the posterior sclera of FD eyes (model + implant group; n =12), compared with model-only (n = 12) and controls eyes (n = 24). Ocular dimensions were monitored via ultrasound. Safety was assessed by electroretinogram, intraocular pressure, and apoptosis assays. The histology structure of regenerated tissue and sclera was shown. Results: The axial length in model + implant eyes was significantly shorter than model-only eyes and the control eyes since 2 weeks after the implantation (13.79 ± 0.23 mm, 15.15 ± 0.33 mm, and 14.70 ± 0.18 mm, P < 0.001) and maintained. The scaffold prompted the in situ regeneration of tissue mimicking the pseudo-lamellar arrangement of collagen fibers and major cell types found in native sclera, which formed an inward therapeutic ridge at the posterior sclera. The simulation indicated the ridge relieved outward macular traction significantly with minimum perturbation to stress distribution outside the central macula. Furthermore, collagen synthesis was prompted within the sclera itself. Conclusions: This innovative strategy, which avoids the long-term complications of foreign body compression, suturing, or tension fixation, effectively reversed myopic eye elongation and induced a therapeutic ridge. Translational Relevance: Demonstration of a degradable scaffold implantation as a treatment for pathological myopia with potential for minimally invasive clinical application was presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.